Table I.
Baseline clinical characteristics of patients with HCC conforming to the Milan Criteria.
| Variable | MWA (n=116) | RES (n=115) | P-value |
|---|---|---|---|
| Age, years mean ± SD | 57.474±9.614 | 54.461±10.366 | 0.647 |
| Sex (M/F), n | 92/24 | 93/22 | 0.767 |
| HBV/HCV/NBNC, n | 90/16/10 | 104/9/2 | 0.016a |
| Cirrhosis (yes/no), n | 108/8 | 108/7 | 0.803 |
| BCLC (0/A/B), n | 11/104/1 | 7/108/0 | 0.375 |
| ALT, IU/l, median (range) | 35 (9.0–99.0) | 40 (14.0–93.0) | 0.145 |
| AST, IU/l, median (range) | 28 (4.0–109.0) | 32 (5.0–95.0) | 0.581 |
| Prothrombin time, sec mean ± SD | 14.387±1.334 | 14.215±1.390 | 0.345 |
| Total bilirubin, µmol/l, median (range) | 18.6 (5.8–59.6) | 15.8 (5.6–54.0) | 0.095 |
| ALB, g/l, median (range) | 41.1 (24.6–48.7) | 40.5 (27.7–52.7) | 0.060 |
| Ascites (absent/present), n | 100/16 | 103/12 | 0.434 |
| Solitary tumor (≤3/>3 cm), n | 51/64 | 41/73 | 0.196 |
| Tumor number (1/2/3), n | 94/17/5 | 97/15/3 | 0.716 |
| AFP (<400/≥400 ng/ml), n | 86/23 | 91/24 | 0.966 |
| Child-Pugh (A/B), n | 90/19 | 99/16 | 0.581 |
a
P<0.05. HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; BCLC, Barcelona Clinic Liver Cancer.